The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to offer a significant substantial decrease in body mass and benefit metabolic function, par… Read More